Form 990 for tax year 2024
Filed by FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND.
Totals
- Total revenue
- $49,306,331
- Total expenses
- $56,828,646
- Contributions and grants received
- $46,591,810
- Grants paid
- $12,782,246
- Program service revenue
- $0
- Investment income
- $2,412,155
- Other revenue
- $302,366
- Total assets, end of year
- $51,274,531
- Total liabilities, end of year
- $42,634,091
- Net assets or fund balances, end of year
- $8,640,440
- Program services expenses (Part IX)
- $46,121,006
- Management and general expenses
- $10,011,541
- Fundraising expenses
- $696,099
- Program service expenses (Part III)
- $46,121,006
Program services were 81.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1e · Government grants (contributions)
$20,189,970
-
1f · All other contributions, gifts and grants
$26,401,840
-
2f · All other program service revenue
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
3 · Investment income
total $2,412,155 · excluded $2,412,155
-
6c · Rental income or loss
real property $0 · personal property $0
-
7c · Gain or loss
securities $0 · other assets $0
-
11a · Other revenue: commission on tax deduction
total $27,171 · excluded $27,171
-
11b · Other revenue: Other Income
total $275,195 · excluded $275,195
-
11d · All other revenue
total $0 · related or exempt $0 · unrelated business $0 · excluded $0
-
11e · Other revenue, total
$302,366
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $977,323 · program services $977,323
-
3 · Grants to foreign organizations and individuals
total $11,804,923 · program services $11,804,923
-
5 · Compensation of officers, directors and key employees
total $2,867,137 · program services $1,690,617 · management and general $997,484 · fundraising $179,036
-
7 · Other salaries and wages
total $14,140,314 · program services $11,983,608 · management and general $1,911,358 · fundraising $245,348
-
8 · Pension plan contributions
total $1,366,163 · program services $1,058,410 · management and general $287,746 · fundraising $20,007
-
9 · Other employee benefits
total $732,173 · program services $481,998 · management and general $250,175
-
10 · Payroll taxes
total $1,442,408 · program services $1,142,324 · management and general $276,543 · fundraising $23,541
-
11a · Fees: management
total $274,641 · program services $144,889 · management and general $129,752
-
11b · Fees: legal
total $806,130 · program services $37,198 · management and general $768,932
-
11c · Fees: accounting
total $464,632 · program services $97,683 · management and general $366,949
-
11g · Fees: other
total $0 · program services $0 · management and general $0 · fundraising $0
-
13 · Office expenses
total $439,254 · program services $392,361 · management and general $46,893
-
14 · Information technology
total $1,779,194 · program services $1,024,796 · management and general $754,398
-
16 · Occupancy
total $1,400,807 · program services $10,118 · management and general $1,390,689
-
17 · Travel
total $2,683,118 · program services $1,842,613 · management and general $812,395 · fundraising $28,110
-
19 · Conferences, conventions and meetings
total $567,402 · program services $465,227 · management and general $102,175
-
23 · Insurance
total $35,903 · program services $0 · management and general $35,903
-
24a · Other expenses: Project contractor
total $13,202,348 · program services $11,978,946 · management and general $1,023,345 · fundraising $200,057
-
24b · Other expenses: EQUIPMENT & SUPPLIES
total $1,169,633 · program services $1,000,991 · management and general $168,642
-
24c · Other expenses: foreign exchange losses
total $680,893 · program services $0 · management and general $680,893
-
24d · Other expenses: TRANSLATION & SPONSORSHIP
total -$5,750 · program services -$13,019 · management and general $7,269
-
24e · All other expenses
total $0 · program services $0 · management and general $0 · fundraising $0
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $13,290,319 · end of year $30,745,582
-
2 · Savings and temporary cash investments
beginning of year $59,797,621 · end of year $9,422,473
-
3 · Pledges and grants receivable
beginning of year $0 · end of year $0
-
4 · Accounts receivable
beginning of year $6,220,098 · end of year $8,838,243
-
5 · Loans and receivables from officers and key people
beginning of year $0 · end of year $0
-
6 · Loans and receivables from disqualified persons
beginning of year $0 · end of year $0
-
7 · Other notes and loans receivable
beginning of year $0
-
8 · Inventories for sale or use
beginning of year $0
-
9 · Prepaid expenses and deferred charges
beginning of year $1,814,846 · end of year $2,274,612
-
10a · Land, buildings and equipment: cost or other basis
$6,989
-
10b · Land, buildings and equipment: accumulated depreciation
$0
-
10c · Land, buildings and equipment, net
beginning of year $6,989 · end of year $6,989
-
11 · Investments: publicly traded securities
beginning of year $0
-
12 · Investments: other securities
beginning of year $0
-
13 · Investments: program-related
beginning of year $0
-
14 · Intangible assets
beginning of year $0
-
15 · Other assets
beginning of year $287,429 · end of year -$13,368
-
17 · Accounts payable and accrued expenses
beginning of year $11,866,468 · end of year $7,587,172
-
18 · Grants payable
beginning of year $0 · end of year $0
-
19 · Deferred revenue
beginning of year $53,388,079 · end of year $35,046,919
-
20 · Tax-exempt bond liabilities
beginning of year $0
-
21 · Escrow or custodial account liability
beginning of year $0
-
22 · Loans and payables to officers and key people
beginning of year $0 · end of year $0
-
23 · Secured mortgages and notes payable
beginning of year $0
-
24 · Unsecured notes and loans payable
beginning of year $0
-
25 · Other liabilities
beginning of year $0 · end of year $0
-
27 · Net assets without donor restrictions
beginning of year $10,660,263 · end of year $6,645,902
-
28 · Net assets with donor restrictions
beginning of year $5,502,492 · end of year $1,994,538
Mission and programs · 2024
Mission
FIND IS AN INTERNATIONAL NON-PROFIT ORGANIZATION THAT ENABLES THE DEVELOPMENT AND DELIVERY OF MUCH-NEEDED DIAGNOSTIC TESTS FOR POVERTY-RELATED DISEASES. FIND ACTS AS A BRIDGE BETWEEN EXPERTS IN TECHNOLOGY DEVELOPMENT, POLICY AND CLINICAL CARE, REDUCING BARRIERS TO INNOVATION AND EFFECTIVE IMPLEMENTATION OF DIAGNOSTIC SOLUTIONS IN LOW-AND-MIDDLE-INCOME COUNTRIES.
Activities or mission (Part I)
THE DEVELOPMENT AND IMPLEMENTATION OF NEW, LOW COST DIAGNOSTICS FOR INFECTIOUS DISEASES FOR USE IN LOW-RESOURCE AREAS.
-
See schedule O
Expenses $13,927,035 · Grants $6,601,315
-
See schedule O
Expenses $5,232,718 · Grants $422,632
-
See schedule O
Expenses $4,890,020 · Grants $627,673
-
Neglected Tropical Diseases (Expenses $4,890,019) NT-P19-003 Chagas Diagnostics Market Sizing Model NT-P16-001 HAT diagnostic algorithm for South Sudan NT-P18-002 INtermediary field evalution report including the RDT performance against the reference standard NT-P19-003 Market Landscape Report of Diagnostic Products for Chagas Disease NT-P18-002 Report detailing the economic analysis of using the SCH CAA RDT instead of current diagnostic tools NT-P16-001 South Sudan HAT Access Database NT-P23-004 Test Directory for Visceral Leishmaniosis Medical Affairs Department (Expenses $4,108,156) Administrative clinical activities Womens Health Department (Expenses $3,248,296) WH-P23-001 Advancing Self collection for HPV testing as a primary cervical cancer screening strategy in sub-saharan Africa WH-P23-001 Assessing feasibility and effectiveness of point-of-care limited HPV genotype tests in cervical cancer screening: a modelling study WH-P23-001 Assessing Feasibility and efficiency of limited HPV genotype targets in cervical cancer screening for sub-saharan Africa WH-P23-001 Human Papillomavirus self-sampling versus provider-sampling in LMIC countries WH-P24-001 Technology Landscape of tools for Anaemia at Primary Health Centers WH-P23-001 Towards 70% cervical cancer screening coverage WH-P23-001 TPPs and relevance of community engagement Pandemic Threats (Expenses $3,232,156) PT-P24-003 Chikungunya test directory PT-P22-006 Diagnostic Accuracy of Three Mpox Lateral Flow Assays for Antigen Detection in the Democratic Republic of Congo and the United Kingdom PT-P22-005 DNO Analysis for Lassa and Yelloe fever in Nigeria PT-P24-002 DxConnect test directory for Lassa PT-P24-002 DxConnect test directory for Nipah PT-P22-006 Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert Mpox (Cepheid) and STANDARD M10 MPX/OPX (SD Biosensor) molecular point-of-care assays for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab sa PT-P24-001 Filovirus Landscape PT-P23-002 i-MCM-Net Mapping Document PT-P24-002 Lassa landscape Manuscript PT-P21-001 License Agreement for Yellow Fever Ag NS1 RDT PT-P24-004 Mpox test directory PT-P24-004 Mpox test tracker PT-P23-002 PDxRI PT-P22-007 Viral Hemorrhagic Fever Strategic Plan PT-P23-002 WHS Roadmap for 100DM for Diagnostics meeting report Antimicrobial Resistance (Expenses $2,773,685) AM-P22-002 A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries FE-P18-003 A Qualitative Thematic Synthesis Study with a discussion of Intervention Design to explore drivers of adherence to prescription in four sites in India AM-P21-001 Affordable blood culture systems from China: in vitro evaluation for use in resource-limited settings AM-P24-001 Antimicrobial Stewardship Modules AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 30 health facilities in India AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 10 Counties in Kenya AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in Kenya AM-P21-001 Blood culture bottles remain efficient months after their expiration date: Implications for low- and middle-income countries. AM-P22-002 Call for public consultation: Target product profile for tests of neonatal sepsis and possible serious bacterial infections in newborns and young infants (final TPP currently in clearance) FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa AM-P22-003 Development of a Novel Fluorescent-Based Lateral Flow Assay for the Detection of Neisseria gonorrhoeae at the Point of Care AM-P22-003 Evaluation of a novel point-of-care lateral flow assay screening for Neisseria gonorrhoeae infection among pregnant women in Zimbabwe AM-P24-001 Guidelines on Prudent Use of Antimicrobials in Animals FE-P18-003 Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in B AM-P22-003 Implementation considerations for a point-of-care Neisseria gonorrhoeae rapid diagnostic test at primary healthcare level in South Africa: a qualitative study AM-P23-006 Investment case for the use of diagnostics for enhancing STI management in South Africa AM-P23-006 Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings AM-P22-002 Multicentre external validation of the Neonatal Healthcare-associated infectiOn Prediction (NeoHoP) score: a retrospective case-control study AM-P24-001 National AMR Surveillance Report AM-P22-003 Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation AM-P23-006 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-002 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-004 Progress made in digitalizing antimicrobial resistance surveillance in a One Health approach in Kenya AM-P21-001 Rapid bacterial identification and resistance detection in positive blood cultures from patients with sepsis in Harare, Zimbabwe: evaluation of a low complexity molecular diagnostic platform AM-P22-003 Usability of a novel lateral flow assay for the point-of-care detection of Neisseria gonorrhoeae: A qualitative time-series assessment among healthcare workers in South Africa
Expenses $22,071,233 · Grants $5,130,626
As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Ayoade AlakijaAYOADE ALAKIJA
CHAIRMAN OF THE BOARD
- Total calculated
- $0
- Hours/week
- 1
-
David HeymannDAVID HEYMANN
MEMBER OF THE BOARD
- Total calculated
- $0
- Hours/week
- 1
-
Frutiger ChristianFRUTIGER CHRISTIAN
MEMBER OF THE BOARD
- Total calculated
- $0
- Hours/week
- 1
-
Kamineni ShobanaKAMINENI SHOBANA
MEMBER OF THE BOARD
- Total calculated
- $0
- Hours/week
- 1
-
Marcel TannerMARCEL TANNER
MEMBER OF THE BOARD
- Total calculated
- $0
- Hours/week
- 1
-
Michele CostaforlazMICHELE COSTAFORLAZ
MEMBER OF THE BOARD
- Total calculated
- $0
- Hours/week
- 1
-
Precious MatsosoPRECIOUS MATSOSO
MEMBER OF THE BOARD
- Total calculated
- $0
- Hours/week
- 1
-
Rick Arthur BrightRICK ARTHUR BRIGHT
MEMBER OF THE BOARD (THRU 8/2024)
- Total calculated
- $0
- Hours/week
- 1
-
Soumya SwaminathanSOUMYA SWAMINATHAN
MEMBER OF THE BOARD (THRU 8/2024)
- Total calculated
- $0
- Hours/week
- 1
-
Cassandra Kelly-CirinoCASSANDRA KELLY-CIRINO
VP, HEALTH PROGRAMMES (thru 8/24)
- Total calculated
- $236,404
- From this org
- $191,471
- From related orgs
- $0
- Other
- $44,933
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $191,471
- Bonus
- $0
- Other
- $0
- Deferred
- $38,430
- Nontaxable benefits
- $6,503
- Filer's total
- $236,404
-
Dayo AdetifaDAYO ADETIFA
CHIEF TRANSFORMATION OFFICER/CEO
- Total calculated
- $173,587
- From this org
- $138,966
- From related orgs
- $0
- Other
- $34,621
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $138,966
- Bonus
- $0
- Other
- $0
- Deferred
- $34,621
- Nontaxable benefits
- $0
- Filer's total
- $173,587
-
Marta Fernandez SuarezMARTA FERNANDEZ SUAREZ
CHIEF TECHNOLOGY OFFICER (thru 10/24)
- Total calculated
- $356,565
- From this org
- $285,980
- From related orgs
- $0
- Other
- $70,585
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $285,980
- Bonus
- $0
- Other
- $0
- Deferred
- $56,899
- Nontaxable benefits
- $13,686
- Filer's total
- $356,565
-
Norma TorresNORMA TORRES
CHIEF OPERATING OFFICER (thru 5/24)
- Total calculated
- $229,953
- From this org
- $215,973
- From related orgs
- $0
- Other
- $13,980
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $215,973
- Bonus
- $0
- Other
- $0
- Deferred
- $13,980
- Nontaxable benefits
- $0
- Filer's total
- $229,953
-
Sergio CarmonaSERGIO CARMONA
CHIEF MEDICAL OFFICER (thru 9/24)
- Total calculated
- $343,382
- From this org
- $284,240
- From related orgs
- $0
- Other
- $59,142
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $254,041
- Bonus
- $30,199
- Other
- $0
- Deferred
- $54,619
- Nontaxable benefits
- $4,523
- Filer's total
- $343,382
-
Sharon SaacksSHARON SAACKS
SENIOR DIRECTOR, PROGRAMME OPERATIONS (thru 7/24)
- Total calculated
- $269,143
- From this org
- $230,858
- From related orgs
- $0
- Other
- $38,285
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $145,852
- Bonus
- $0
- Other
- $85,006
- Deferred
- $38,285
- Nontaxable benefits
- $0
- Filer's total
- $269,143
-
William RodriguezWILLIAM RODRIGUEZ
CHIEF EXECUTIVE OFFICER (thru 6/24)
- Total calculated
- $223,051
- From this org
- $197,568
- From related orgs
- $0
- Other
- $25,483
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $197,568
- Bonus
- $0
- Other
- $0
- Deferred
- $25,483
- Nontaxable benefits
- $0
- Filer's total
- $223,051
-
Willo BrockWILLO BROCK
EXECUTIVE VP, EXTERNAL AFFAIRS (thru 6/24)
- Total calculated
- $163,705
- From this org
- $163,705
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $163,705
- Bonus
- $0
- Other
- $0
- Deferred
- $0
- Nontaxable benefits
- $0
- Filer's total
- $163,705
-
Darryl EnglishDARRYL ENGLISH
DEPUTY DIRECTOR, FINANCE (THRU 11/24)
- Total calculated
- $414,021
- From this org
- $342,536
- From related orgs
- $0
- Other
- $71,485
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $342,536
- Bonus
- $0
- Other
- $0
- Deferred
- $71,485
- Nontaxable benefits
- $0
- Filer's total
- $414,021
-
Kevin TettehKEVIN TETTEH
DIRECTOR, MALARIA FEVER PROGRAMME
- Total calculated
- $224,954
- From this org
- $181,958
- From related orgs
- $0
- Other
- $42,996
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $181,958
- Bonus
- $0
- Other
- $0
- Deferred
- $42,996
- Nontaxable benefits
- $0
- Filer's total
- $224,954
-
Sanjay SarinSANJAY SARIN
VP, ACCESS (thru 10/24)
- Total calculated
- $232,372
- From this org
- $232,372
- From related orgs
- $0
- Other
- $0
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $232,372
- Bonus
- $0
- Other
- $0
- Deferred
- $0
- Nontaxable benefits
- $0
- Filer's total
- $232,372
-
Beatrice MoutonBEATRICE MOUTON
DIRECTOR, HUMAN RESOURCES
- Total calculated
- $313,006
- From this org
- $260,701
- From related orgs
- $0
- Other
- $52,305
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $260,701
- Bonus
- $0
- Other
- $0
- Deferred
- $44,367
- Nontaxable benefits
- $7,938
- Filer's total
- $313,006
-
Brooke NicholsBROOKE NICHOLS
SENIOR DIRECTOR, IMPACT
- Total calculated
- $296,689
- From this org
- $265,429
- From related orgs
- $0
- Other
- $31,260
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $265,429
- Bonus
- $0
- Other
- $0
- Deferred
- $31,260
- Nontaxable benefits
- $0
- Filer's total
- $296,689
-
Maria Cecilia Ferreyra ArellanoMARIA CECILIA FERREYRA ARELLANO
Director of AMR Programme
- Total calculated
- $250,024
- From this org
- $213,012
- From related orgs
- $0
- Other
- $37,012
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $213,012
- Bonus
- $0
- Other
- $0
- Deferred
- $30,675
- Nontaxable benefits
- $6,337
- Filer's total
- $250,024
-
Morten RuhwaldMORTEN RUHWALD
DIRECTOR, TUBERCULOSIS PROGRAMME
- Total calculated
- $298,773
- From this org
- $244,800
- From related orgs
- $0
- Other
- $53,973
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $244,800
- Bonus
- $0
- Other
- $0
- Deferred
- $44,029
- Nontaxable benefits
- $9,944
- Filer's total
- $298,773
-
Shaukhat Ali KhanSHAUKHAT ALI KHAN
Director Strategic Information
- Total calculated
- $289,581
- From this org
- $235,091
- From related orgs
- $0
- Other
- $54,490
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $235,091
- Bonus
- $0
- Other
- $0
- Deferred
- $44,098
- Nontaxable benefits
- $10,392
- Filer's total
- $289,581
-
Louisa Chaubert
DIRECTOR OF FINANCE (THRU 12/23)
- Total calculated
- $103,443
- From this org
- $95,808
- From related orgs
- $0
- Other
- $7,635
- Hours/week
- 0
Schedule J breakdown matched by us
- Base
- $0
- Bonus
- $0
- Other
- $95,808
- Deferred
- $7,635
- Nontaxable benefits
- $0
- Filer's total
- $103,443
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Compensation survey or study
- 3 · Approval by the board or compensation committee
- 4a · Severance or change-of-control payment
Answered no
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
The filer's explanations (Part III)
- Schedule J, Part III
- The following individuals received severance payments in 2024: -Sharon Saacks received a severance payment of $85,006 in 2024. -Louisa Chaubert received a severance payment of $95,808 in 2024.
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
$506,168
LABORATORY STRENGTHENING TO SUPPORT CLINICAL CARE AND RESEARCH
-
DIAGNOSTIC CONSULTING NETWORK
$410,848
DEVELOPMENT OF DIAGNOTIC TESTS
-
Clinton Health Access Initiative Inc
$288,213
TO SUPPORT TB ELIMINATION EFFORTS
-
American Society of Tropical Med
$50,000
PUBLICATION OF JOURNAL SUPPLEMENT
-
QUANTIGEN
$40,570
ACCELERATING TOOLS TO DRIVE TUBERCULOSIS DETECTION
-
GENOMICS TRAININGS. SUPPORTING THE AFRICA CDC WORKFORCE DEVELOPMENT EFFORT FOR PATHOGEN GENOMIC SURVEILLANCE
-
DIMAGI INC
$30,457
PRODUCTION OF MOBILE PHONE APPS THAT COLLECTS DATA FROM RAPID VITRO DIAGNOSTIC TEST AND THAT CAN AID AN RDT USER IN INTERPRETING THE TEST RESULTS
-
DRIVING EQUITABLE ACCESS TO TESTING IN LMICS THROUGH EFFECTIVE AND AFFORDABLE TESTS AND INFRASTRUCTURE
-
Drugs & Diagnostics for Tropical Diseases
$10,011
RAPID DIAGNOSTIC TESTING FOR BURULI ULCER
-
$9,802
PROJECT AGREEMENT WITH HARVARD FOR SEQ&TREAT MUTATIONS CATALOGUE WORK
The 10 largest by cash amount. The API serves every itemized grant.
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 3
- Employees, agents and contractors (line 3c)
- 210
- Expenditures and investments (line 3c)
- $52,547,847
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Activities by region (Part I)
| Region | Offices | Employees | Activity | Specific services | Expenditures |
|---|---|---|---|---|---|
| Sub-Saharan Africa | 1 | 24 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $11,437,079 |
| South Asia | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $2,838,911 |
| East Asia and the Pacific | 1 | 7 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $2,516,239 |
| Europe (Including Iceland and Greenland) | 1 | 179 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $34,190,111 |
| South America | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $718,880 |
| North America (Canada & Mexico only) | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $536,256 |
| Russia and Neighboring States | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $78,098 |
| Middle East and North Africa | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $191,790 |
| Central America and the Caribbean | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $40,483 |
Grants to organizations, by region (Part II)
The purpose of each grant is not shown.
| Region | Cash grants | Manner of disbursement | Noncash assistance | Noncash description | Valuation |
|---|---|---|---|---|---|
| Sub-Saharan Africa | $5,538,205 | ELEC FD TRAN | — | N/A | N/A |
| South Asia | $204,033 | ELEC FD TRAN | — | N/A | N/A |
| East Asia and the Pacific | $866,217 | ELEC FD TRAN | — | N/A | N/A |
| Europe (Including Iceland and Greenland) | $4,581,949 | ELEC FD TRAN | — | N/A | N/A |
| South America | $532,607 | ELEC FD TRAN | — | N/A | N/A |
| Russia and Neighboring States | $54,879 | ELEC FD TRAN | — | N/A | N/A |
| Middle East and North Africa | $27,033 | ELEC FD TRAN | — | N/A | N/A |
- Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
- 52
- Other grantees (Part II line 3)
- 57
- Transferred property to a foreign corporation during the year (line 1)
- No
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- No
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Related organizations on this return
Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.
-
FIND INDIA
PROGRAM SERVICES · IN · controlled entity
Directly controlled by FIND SWISS
-
FIND DX NPC
PROGRAM SERVICES · SF · controlled entity
Directly controlled by FIND SWISS
-
FIND DX KENYA
PROGRAM SERVICES · KE · controlled entity
Directly controlled by FIND SWISS
Provenance
- Return type
- form_990
- Tax year
- 2024
- Filed
- 17 November 2025
- IRS schema version
- 2024v5.1
- Source object
- 202523219349318337
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.